Member Info for Timster

Concerning though isn't it, Alan sounds concerned, the way he said "indeed", I'm concerned.
And why no video so we could read his concerned body language, very concerning.

Learn how to use URL shorteners please.
http://shorturl.at/GNPS8

Round and round and round.

4 days we will get more information, and commentary from oncology opinion leaders.

Then we start again, round and round and round....

Source?
And depends

To me.... To you.....to me......To you

Another miserable twunt takes over the board.

Only because he's concerned and cares though.

I'd much rather he'd just produced pages of scientific script then we could have argued (even more ) about what it means.

I don't think there is much confusion as to what unequivocally means? Although evidently there is among some...

It's almost like Alan has seen some data...

6,14,15 prints
But most importantly the 1 code......
Sujood? Can it be true?

It's flying Hurstbot

Pleasure...

Not sure anyone on here who isn't on the telegram group cares really, I know I don't

Neut , if we all thought the same thing, we'd be on the telegram group.

Baba vanga

Rns tomorrow?

Or is it a shove to those with tentative offers to say, "look who we have in a room next Thursday" wait till we tell them what we have...

That theory makes the science day and the fact it's only those with the cash to splash as invited guests also a conundrum.

Why invite them if they have a deal in the bag and loads of offers?

It's not likely an up yours to the UK investment base? Or is it?

/p100100
'h-+8

As was pointed out to me though it's therepeutic focussed no DX discussed.

Avacta to Host Therapeutics Division Science Day on 23rd February 2023

For this:
The Diagnostics Division is now focused on developing a broader pipeline of new IVD products outside of COVID-19 to drive future revenues and the profitability of the Division. This pipeline is designed to deliver, over the longer term, a full portfolio of IVD products with a focus on decentralised testing for professionals and consumers. The Company is addressing four key areas of respiratory, infectious and cardiovascular disease, cancer and general health and well-being (e.g. hormones, vitamins). The Company is exploring multiple pathways to develop this portfolio of IVD products and revenue as rapidly as possible.

And the TiTs are in full flow